Back to search

Article

Clinical Evidence of Initiating a Very Low Dose of Sacubitril/Valsartan; Beyond the PARADIGM-HF and PIONEER-HF: A Prospective Observational Analysis

2021-05-13

Abstract excerpt

<h4>Aims: </h4> Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and preventing hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). However, patients often do not receive sacubitril/valsartan because of concerns about hypotension. We examined the feasibility of initiating sacubitril/valsartan at a very low dose (VLD) in potentially intole...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f3b5df13-000e-5a01-a0d5-69cdf4704f6b
DOI
10.21203/rs.3.rs-512308/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical Evidence of Initiating a Very Low Dose of Sacubitril/Valsartan; Beyond the PARADIGM-HF and PIONEER-HF: A Prospective Observational AnalysisDOI 10.21203/rs.3.rs-512308/v1
Select a neighboring publication to make it the new centre.